Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

Cost and burden of gastroesophageal reflux disease among patients with persistent symptoms despite proton pump inhibitor therapy: an observational study in France.

Bruley des Varannes S, Löfman HG, Karlsson M, Wahlqvist P, Ruth M, Furstnau ML, Despiégel N, Stålhammar NO.

BMC Gastroenterol. 2013 Feb 28;13:39. doi: 10.1186/1471-230X-13-39.

2.

Burden of gastro-oesophageal reflux disease in patients with persistent and intense symptoms despite proton pump inhibitor therapy: A post hoc analysis of the 2007 national health and wellness survey.

Toghanian S, Johnson DA, Stålhammar NO, Zerbib F.

Clin Drug Investig. 2011 Oct 1;31(10):703-15. doi: 10.2165/11595480-000000000-00000.

PMID:
21756007
3.

Partial response to proton pump inhibitor therapy for GERD: observational study of patient characteristics, burden of disease, and costs in the USA.

Stålhammar NO, Spiegel BM, Granstedt Löfman H, Karlsson M, Wahlqvist P, Næsdal J, Nelson MT, Despiégel N.

Pragmat Obs Res. 2012 Dec 5;3:57-67. eCollection 2012.

4.

Impact of gastro-oesophageal reflux disease on work productivity despite therapy with proton pump inhibitors in Germany.

Gross M, Beckenbauer U, Burkowitz J, Walther H, Brueggenjuergen B.

Eur J Med Res. 2010 Mar 30;15(3):124-30.

5.

The impact of proton pump inhibitor compliance on health-care resource utilization and costs in patients with gastroesophageal reflux disease.

Gosselin A, Luo R, Lohoues H, Toy E, Lewis B, Crawley J, Duh MS.

Value Health. 2009 Jan-Feb;12(1):34-9. doi: 10.1111/j.1524-4733.2008.00399.x. Epub 2008 Jul 15.

6.

Two-year results of intermittent electrical stimulation of the lower esophageal sphincter treatment of gastroesophageal reflux disease.

Rodríguez L, Rodriguez P, Gómez B, Ayala JC, Oxenberg D, Perez-Castilla A, Netto MG, Soffer E, Boscardin WJ, Crowell MD.

Surgery. 2015 Mar;157(3):556-67. doi: 10.1016/j.surg.2014.10.012. Epub 2014 Nov 6.

7.

Factors affecting response to proton pump inhibitor therapy in patients with gastroesophageal reflux disease: a multicenter prospective observational study.

Matsuhashi N, Kudo M, Yoshida N, Murakami K, Kato M, Sanuki T, Oshio A, Joh T, Higuchi K, Haruma K, Nakada K.

J Gastroenterol. 2015 Dec;50(12):1173-83. doi: 10.1007/s00535-015-1073-0. Epub 2015 Apr 8.

PMID:
25851931
8.

Gastroesophageal reflux disease in primary care: using changes in proton pump inhibitor therapy as an indicator of partial response.

Ruigómez A, Johansson S, Wernersson B, Fernández Cantero O, García Rodríguez LA.

Scand J Gastroenterol. 2012 Jul;47(7):751-61. doi: 10.3109/00365521.2012.679682. Epub 2012 Apr 23.

PMID:
22519917
9.

Relationship between symptom load of gastro-oesophageal reflux disease and health-related quality of life, work productivity, resource utilization and concomitant diseases: survey of a US cohort.

Wahlqvist P, Karlsson M, Johnson D, Carlsson J, Bolge SC, Wallander MA.

Aliment Pharmacol Ther. 2008 May;27(10):960-70. doi: 10.1111/j.1365-2036.2008.03671.x. Epub 2008 Feb 29.

10.

Greater loss of productivity among Japanese workers with gastro-esophageal reflux disease (GERD) symptoms that persist vs resolve on medical therapy.

Suzuki H, Matsuzaki J, Masaoka T, Inadomi JM.

Neurogastroenterol Motil. 2014 Jun;26(6):764-71. doi: 10.1111/nmo.12319. Epub 2014 Feb 25.

PMID:
24602100
11.

[Insufficient symptom control under long-term treatment with PPI in GERD - fact or fiction?].

Labenz J, Labenz G, Stephan D, Willeke F; LOPA-Studiengruppe.

MMW Fortschr Med. 2016 May 25;158 Suppl 4:7-11. doi: 10.1007/s15006-016-8303-0. Epub 2016 May 25. German.

PMID:
27221555
12.

Disease-specific cost savings of treating nighttime versus daytime gastroesophageal reflux disease in an employed population.

Doan QV, Lange SM, Elfant A, Aguilar D, Reyes E, Lynn RB, Dubois RW.

J Med Econ. 2008;11(1):23-40. doi: 10.3111/13696990701815545.

PMID:
19450108
13.

Validation of a short questionnaire in English and French for use in patients with persistent upper gastrointestinal symptoms despite proton pump inhibitor therapy: the PASS (Proton pump inhibitor Acid Suppression Symptom) test.

Armstrong D, Veldhuyzen SJ, Chung SA, Shapiro CM, Dhillon S, Escobedo S, Chakraborty BK, Mann V, Tanser L, Nevin K.

Can J Gastroenterol. 2005 Jun;19(6):350-8.

PMID:
15997268
14.
15.

Variation of health-care resource utilization according to GERD-associated complications.

Gerson LB, McLaughlin T, Balu S, Jackson J, Lunacsek O.

Dis Esophagus. 2012 Nov-Dec;25(8):694-701. doi: 10.1111/j.1442-2050.2011.01313.x. Epub 2012 Jan 31.

PMID:
22292744
16.

The burden of disrupting gastro-oesophageal reflux disease: a database study in US and European cohorts.

Toghanian S, Wahlqvist P, Johnson DA, Bolge SC, Liljas B.

Clin Drug Investig. 2010;30(3):167-78. doi: 10.2165/11531670-000000000-00000.

PMID:
20155989
17.
18.

Characteristics of refractory gastroesophageal reflux disease (GERD) symptoms -is switching proton pump inhibitors based on the patient's CYP2C19 genotype an effective management strategy?

Takeuchi T, Oota K, Harada S, Edogawa S, Kojima Y, Sanomura M, Sakaguchi M, Hayashi K, Hongoh Y, Itabashi T, Kitae H, Hoshimoto M, Takeuchi N, Higuchi K.

Intern Med. 2015;54(2):97-105. doi: 10.2169/internalmedicine.54.3412. Epub 2015 Jan 15.

19.

Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they?

de Bortoli N, Martinucci I, Savarino E, Bellini M, Bredenoord AJ, Franchi R, Bertani L, Furnari M, Savarino V, Blandizzi C, Marchi S.

Neurogastroenterol Motil. 2014 Jan;26(1):28-35. doi: 10.1111/nmo.12221. Epub 2013 Aug 29.

PMID:
23992024
20.

Effectiveness of add-on therapy with domperidone vs alginic acid in proton pump inhibitor partial response gastro-oesophageal reflux disease in systemic sclerosis: randomized placebo-controlled trial.

Foocharoen C, Chunlertrith K, Mairiang P, Mahakkanukrauh A, Suwannaroj S, Namvijit S, Wantha O, Nanagara R.

Rheumatology (Oxford). 2017 Feb;56(2):214-222. doi: 10.1093/rheumatology/kew216. Epub 2016 May 13.

PMID:
27179107

Supplemental Content

Support Center